enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. New schizophrenia drug gets FDA approval, taking novel ... - AOL

   www.aol.com/news/schizophrenia-drug-gets-fda...

   September 27, 2024 at 2:25 PM. New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder. A new drug has been approved for the treatment of schizophrenia in adults ...

3. This FDA-approved drug promises a new way to treat schizophrenia

   www.aol.com/fda-approved-drug-promises-way...

   Updated September 29, 2024 at 12:48 PM. People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday ...

4. Bristol Myers wins US FDA approval for new type of ...

   www.aol.com/news/us-fda-approves-bristol-myers...

   September 27, 2024 at 6:06 AM. By Bhanvi Satija and Michael Erman. (Reuters) -The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it ...

5. Ulotaront - Wikipedia

   en.wikipedia.org/wiki/Ulotaront

   Ulotaront (INN; [1] developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. [2][3] The medication was discovered in collaboration between PsychoGenics Inc. and Sunovion Pharmaceuticals [2] (which was subsequently merged ...

6. Xanomeline/trospium chloride - Wikipedia

   en.wikipedia.org/wiki/Xanomeline/trospium_chloride

   In September 2024, it was approved for medical use in the United States. [1] [2] It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. [2]

7. Brilaroxazine - Wikipedia

   en.wikipedia.org/wiki/Brilaroxazine

   RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...